this post was submitted on 13 Jun 2026
21 points (95.7% liked)

World News

56931 readers
1831 users here now

A community for discussing events around the World

Rules:

Similarly, if you see posts along these lines, do not engage. Report them, block them, and live a happier life than they do. We see too many slapfights that boil down to "Mom! He's bugging me!" and "I'm not touching you!" Going forward, slapfights will result in removed comments and temp bans to cool off.

We ask that the users report any comment or post that violate the rules, to use critical thinking when reading, posting or commenting. Users that post off-topic spam, advocate violence, have multiple comments or posts removed, weaponize reports or violate the code of conduct will be banned.

All posts and comments will be reviewed on a case-by-case basis. This means that some content that violates the rules may be allowed, while other content that does not violate the rules may be removed. The moderators retain the right to remove any content and ban users.


Lemmy World Partners

News !news@lemmy.world

Politics !politics@lemmy.world

World Politics !globalpolitics@lemmy.world


Recommendations

For Firefox users, there is media bias / propaganda / fact check plugin.

https://addons.mozilla.org/en-US/firefox/addon/media-bias-fact-check/

founded 3 years ago
MODERATORS
 

Japanese pharmaceutical companies are investing more in China, the world's second-largest market, aiming to tap the rapidly improving drug discovery capabilities of Chinese partners to find promising new candidates.

Astellas Pharma will open a research and development center -- the company's first in China -- in Beijing as soon as this year.

The company already has sales and clinical trial facilities in Beijing and Shanghai, as well as a production base in Shenyang. The Beijing R&D hub will handle drug discovery.

Daiichi Sankyo is investing about 1.1 billion yuan ($162 million) to increase China production capacity by starting operations at a Shanghai pharmaceutical production facility in fiscal 2030.

Takeda Pharmaceutical and Eisai have partnered with Chinese biotech companies to expand their pools of drug candidates.

top 2 comments
sorted by: hot top controversial new old
[–] avidamoeba@lemmy.ca 1 points 3 weeks ago

As has American pharma.

[–] czardestructo@lemmy.world -1 points 3 weeks ago

We were almost finished training them to do electrical mechanical and software engineering. Might as well move on to the life sciences.